Author

Mallorie Werner

OpenAlex ID: A5111318734

Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-Myositis phase I/II trial

2024 · Jenell Volkov, Daniel Nunez, et al. · Molecular Therapy · 54

CD19 CAR T-cell therapy is feasible for patients with pemphigus vulgaris treated without lymphodepletion in the RESET-PV trial

2026 · Daniel Nunez, Jason Stadanlick, et al. · Blood · 4

Case study of resecabtagene autoleucel in a subject with diffuse cutaneous systemic sclerosis treated in the RESET-SSc trial

2025 · Daniel Nunez, Jenell R. Volkov, et al. · Molecular Therapy Advances · 2

Reset Sle: Clinical Trial Evaluating Caba-201, a Fully Human, Autologous 4-1bb Anti-cd19 Car T Cell Therapy in Nonrenal Sle and Lupus Nephritis

2025 · Saira Sheikh, Vimal Derebail, et al. · The Journal of Rheumatology · 2

RESET-MG: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), a Fully Human, Autologous 4-1BB-CD19-CAR T Cell Therapy in Generalized Myasthenia Gravis (gMG) (S14.003)

2026 · Ali Habib, Stefan Ciurea, et al. · Neurology

Mechanistic basis of the acute safety profile of rese-cel, an autologous CD19-CAR T, in patients with autoimmune disease treated in four ongoing phase 1/2 clinical trials

2025 · Daniel Nunez, Jenell Volkov, et al. · Blood

Works count: 6

Citation count: 62

H-index: 2

I10-index: 1